Chlamydia pneumoniae infection can exacerbate atherosclerosis in animals. To test the hypothesis that antibiotic therapy inhibits the atherogenic effects of C. pneumoniae infection, 10-week-old apolipoprotein E (ApoE) null mice were infected with C. pneumoniae or placebo, were treated for 2 weeks after infection with azithromycin or placebo, and were killed at 20 weeks of age. Infection did not affect the size of the aortic lesion, and antibiotic treatment had no effect. Another group of mice, 12-week-old ApoE mice, were infected with C. pneumoniae or placebo, were treated for 2 weeks after infection with azithromycin or placebo, and were killed at 26 weeks of age. C. pneumoniae infection increased the size of the lesion in infected mice, but azithromycin did not reduce the size of the aortic lesion in infected mice.
In an attempt to define more clearly a causal role for C. pneumoniae in atherogenesis, several prospective studies explored the use of antibiotics and clinical outcomes among patients with coronary artery disease. These studies have had mixed results: In one, antibiotic usage was correlated with a reduction in adverse events following myocardial infarction [50] , another found no association between antibiotic usage and clinical improvement [51] , and a third showed a nonsignificant trend toward benefit in patients with unstable angina treated with antibiotics [52] . Several large prospective trials are now underway to measure the effect of antibiotics on the clinical outcomes of patients at high risk for coronary events [51, 53, 54] . These trials are based on the assumption that treatment with antibiotics chosen for their efficacy in treating acute C. pneumoniae infections will stabilize plaques and therefore decrease cardiovascular events.
Rabbit and mouse models of atherogenesis have been used to determine whether C. pneumoniae can induce de novo plaque formation [12, 18, 20, [55] [56] [57] [58] [59] . Muhlestein et al. [18] and Fong et al. [57] showed that infection with C. pneumoniae increases intimal thickness and causes atherosclerosis in 30%-40% of infected New Zealand White rabbits. This effect was diminished by treatment of acute infection with high-dose azithromycin administered once weekly, starting 5 days after inoculation and continuing for 10 weeks until death. In mice, C. pneumoniae has been implicated in increasing fatty streak lesion formation in apolipoprotein E (ApoE) null mice and low-density lipoprotein (LDL) receptor null mice [58, 59] .
Serologic studies show that most people are infected with C. pneumoniae in the first 3-4 decades of life [60] . Since the majority of adolescents and young adults have visible fatty streaks Figure 1 . Experimental design. Two groups (schedules) of mice were inoculated with Chlamydia pneumoniae and were treated. Mice in group 1 were inoculated with C. pneumoniae or placebo at 10 and 12 weeks of age, were treated with azithromycin or placebo at 14 and 15 weeks, and were killed at 20 weeks. Mice in group 2 were inoculated with C. pneumoniae or placebo at 12 and 14 weeks, were treated with azithromycin or placebo at 16 and 17 weeks, and were killed at 26 weeks.
in their aorta and coronary arteries, C. pneumoniae infection may affect the development of fatty streaks. The lesions found in the early decades of life may be precursors of the fibrous plaques that cause cardiovascular events in later life; decreasing fatty streaks may prevent future unstable coronary syndromes.
This study was designed to test 2 hypotheses: (1) that C. pneumoniae infection accelerates fatty streak and fibrous plaque formation in mice and (2) that treatment with antibiotics after an acute C. pneumoniae infection prevents an increase in fatty streak and fibrous plaque formation. We administered azithromycin or placebo to ApoE null mice that either had been inoculated or had not been inoculated with C. pneumoniae and then observed the development of fatty streaks and fibrous plaques.
Materials and Methods
Animal studies. Eight-to 10-week old ApoE-deficient female mice (back-crossed 16 generations with C57BL/6J mice) were obtained from Jackson Laboratories and were fed standard mouse chow (Purina) throughout the experiment. The mice were housed in microisolator cages and were handled only in sterile hoods.
In each set of experiments, 10 mice were mock infected with sterile medium and were treated with placebo, 10 mice were mock infected with sterile medium and were treated with azithromycin, 10 mice were infected with C. pneumoniae and were treated with placebo, and 10 mice were infected with C. pneumoniae and were treated with azithromycin. This set of experiments was repeated for 2 different schedules (figure 1). For the first schedule, mice were inoculated with C. pneumoniae or sterile medium at 10 and 12 weeks of age, were treated with azithromycin or placebo at 14 and 15 weeks of age, and were killed at 20 weeks of age. For the second schedule, mice were inoculated with C. pneumoniae or sterile medium at 12 and 14 weeks of age, were treated with azithromycin or placebo at 16 and 17 weeks of age, and were killed at 26 weeks of age. The entire experiment then was repeated once, so that a total of 80 mice were treated according to the first schedule and 80 mice were treated according to the second schedule.
The 2 different schedules were developed according to the following rationale. We infected 1 group of ApoE null mice at 10-12 weeks of age when fatty streaks (collections of foam cells) first develop and the other group at 12-14 weeks of age when intermediate lesions (containing foam cells and spindle-shaped smooth muscle cells) begin to appear. The mice were inoculated at different ages, to determine whether fatty streaks or intermediate lesions have different susceptibilities to infection. Both groups then were treated with antibiotics 2 and 3 weeks after the last infection. The mice in the first group were killed at 20 weeks of age, the time at which fibrous plaques (necrotic core covered by a fibrous smooth muscle cell cap) appear, to determine whether infection or treatment affects fibrous plaque development. The mice in the second group were killed at 26 weeks of age, to determine whether infection or treatment affected advanced lesions (partial destruction of medial cells and calcification). The mice were studied at different ages to determine whether infection affects the development of different lesions, fibrous plaques, and advanced lesions.
All mice were killed after a 16-h fast. The mice were anesthetized with pentofane and then were exsanguinated via the inferior vena cava. Blood drawn from the inferior vena cava at the level of the renal veins was collected at the time of death in heparinized syringes, treated with EDTA, and centrifuged. Plasma was flash frozen and stored at Ϫ70ЊC. At death, the ventricles, aortic arch, right lung, and spleen were harvested and frozen at Ϫ70ЊC.
C. pneumoniae strain and inoculum. C. pneumoniae A-03, a human atheroma isolate [42] , was grown in HEp-2 cells, as described elsewhere [61] . Purified elementary bodies were frozen in Chlamydia medium with glucose and antibiotics (CMGA) at a concentration of 108 inclusion-forming units (ifu)/mL and were stored at Ϫ70ЊC. All murine infections were done by using a single preparation of C. pneumoniae. Mice were anesthetized with pentofane and were intranasally administered 50 mL of either sterile CMGA or CMGA containing ifu of C. pneumoniae. Mice NOTE. Data are no. positive/total no. tested. Mice at 12 and 14 weeks of age were sham inoculated or inoculated with C. pneumoniae, were treated with placebo or azithromycin at 16 and 17 weeks of age, and were killed at 26 weeks. Antibodies to C. pneumoniae were present in all mice inoculated with C. pneumoniae but were absent from sham-inoculated mice ( mice/each of 4 groups). n p 5 C. pneumoniae DNA was present in 20 mice inoculated with C. pneumoniae, whether they were treated with azithromycin or with placebo; C. pneumoniae DNA was absent from 20 sham-inoculated mice. Treatment with azithromycin. Mice were given 24 mg/kg azithromycin in an aqueous suspension (gift of Pfizer Laboratories) by oral intubation at 2 weeks and at 3 weeks after the second infection. Untreated mice were given sterile water by oral intubation in the same manner as the treated mice.
Serology. Antibodies to C. pneumoniae were measured by the microimmunofluorescence test, as described elsewhere [62] . IgG antibodies were measured by using mouse serum sample dilutions of 1:16 to 1:1024. A goat anti-mouse IgG was used as the secondary antibody conjugated to fluorescein. Antibodies were measured in 20 of the 80 mice in schedule 2 (5 randomly selected from the 10 mice in each of the following groups: the noninfected nontreated, infected but not treated, noninfected but treated, and infected and treated groups). All tests were done by laboratory personnel who were unaware of the study treatment arms.
Lipid profile. Plasma samples from 3 mice in each of the 4 groups inoculated at 12 and 14 weeks were submitted to the Johns Hopkins Hospital Clinical Laboratory for the determination of total cholesterol, high-density lipoprotein (HDL), and triglycerides. The reported LDL was calculated as follows: total cholesterol p . HDL ϩ triglycerides/5 ϩ LDL PCR of C. pneumoniae. DNA was extracted from tissue of 40 mice in each schedule by standard techniques and was analyzed by touchdown enzyme time release PCR [63] . The PCR reaction mix included DNA from murine tissues, primers CPN90 and CPN91 (which flank a 195-bp portion of the 16S rRNA genes), and Taq polymerase (HotStarTaq; Qiagen). The initial denaturing incubation at 95ЊC for 75 s was followed by 60 cycles of denaturation at 95ЊC for 45 s, annealing from 65ЊC to 55ЊC for 45 s, and extension at 72ЊC for 60 s. During the first 40 cycles, the annealing temperature of 65ЊC was lowered 1ЊC every 4 cycles, and then the annealing temperature was held constant at 55ЊC for the remaining 20 cycles. The PCR products were fractionated on 3% agarose Trisborate EDTA gels and were stained with ethidium bromide.
Quantification of atherosclerotic lesions in the aortic root. Aortas were harvested and quantified as described by Paigen et al. [64] . Mice were exsanguinated, and their hearts were perfused first with normal saline and then with optimum cutting temperature (OCT) compound (VWR Scientific Products). The hearts and ascending aortas were dissected, and the hearts were cut in half, perpendicular to the plane of the atria just below the atria, were mounted in OCT blocks, and were frozen. The blocks were cut in 10-mm sections, and every fifth section, starting from the first section distal to the aortic valve leaflets, was stained with oil red O (ORO) and counterstained with hematoxylin. Five sections were stained per aorta. The sections were photographed with a digital camera (Polaroid), using identical settings for exposure, lighting, and magnification. The number of pixels of staining was calculated with a macro created in Adobe Photoshop to eliminate observer bias. The values obtained for the 5 sections were averaged; this value represents the relative mean area index of ORO staining for a section of the aortic root in any given mouse and is termed the atherosclerotic lesion index. The mean and SD were calculated within each group of mice. The statistical significance of the differences among experimental groups was compared by Wilcoxon rank sum test.
Results

Verification of infection by PCR and serology.
Serologic testing detected antibody to C. pneumoniae at an IgG titer of 1:128 in all mice infected at week 12 and killed at week 26 (table 1) . No antibodies were detected in mock-infected mice. We found that C. pneumoniae DNA persists in the lungs of infected mice, even after azithromycin treatment. The PCR detected C. pneumoniae DNA in 70% of tissues from untreated mice and in 50% of treated mice 8 weeks after infection (table  1) . As expected, the PCR did not detect C. pneumoniae DNA in any sham-infected animals (table 1) .
Lipid profile. There was no significant difference in total cholesterol, LDL, or HDL in the various experimental groups of mice that were killed at 26 weeks (table 2) . However, triglyceride levels were significantly higher in infected versus sham-inoculated mice in both azithromycin treated and untreated groups ( ). in infected mice. We also administered azithromycin to noninfected mice, since azithromycin and macrolide antibiotics have anti-inflammatory effects [65] [66] [67] ; however, azithromycin had no effect on lesion size in noninfected animals ( figure 3 ). In contrast, C. pneumoniae infection increased aortic lesion size in 26-week-old mice infected at 12 and 14 weeks of age, compared with that in sham-infected mice ( ; figure 3 ). How-P ! .01 ever, treatment with azithromycin did not affect lesion size in infected mice, compared with that of placebo treatment.
Discussion
Our major findings were that C. pneumoniae infection increases aortic lesion size but that azithromycin treatment does not reduce this effect of infection. In other studies, C. pneumoniae increased aortic lesions in a murine model of atherosclerosis [58] . Our results are consistent with those of Hu et al. [59] , who showed that C. pneumoniae infection increases aortic lesion area in LDL receptor knockout mice that were fed a high cholesterol diet, compared with that of uninfected mice. Similar to our results, the difference between infected and uninfected mice became apparent at 6-9 months of age but not at earlier time points. However, in our experiment, mice were infected twice 2 weeks apart, whereas Hu et al. infected their mice once every month for the duration of their experiment.
Another difference between our study and that of Hu et al. [59] was that C. pneumoniae infection had no effect on arteriosclerosis in LDL receptor null mice, unless the mice were fed an atherogenic diet. In contrast, C. pneumoniae infection increased arteriosclerosis in the ApoE null mice in our study when fed a normal mouse chow diet. One possible explanation for this difference is that the consequences of a lack of ApoE are more severe than of a lack of LDL receptor. The lesions found in LDL receptor knockout mice are primarily fatty streaks, an early lesion in arteriosclerosis. In contrast, most of the lesions in the ApoE mouse at 26 weeks have fibrous caps, a sign of a more mature arteriosclerotic lesion. If C. pneumoniae is more tropic to cells that contribute to the pathogenesis of fibrous plaques or if the microenvironment of the fibrous plaque favors the replication of C. pneumoniae more than that of a fatty streak, it is possible that C. pneumoniae could initially replicate to higher levels and cause more inflammation in ApoE than in LDL receptor null vessels.
Our findings extend the observations of Moazed et al. [58] . They showed that C. pneumoniae infection of ApoE null mice at 8, 9, and 10 weeks of age causes a 2.4-fold increase in the area of fatty streaks in the aortic arch at 16 weeks of age. However, this difference diminished to 1.5-fold at 20 weeks of age. In our study, infection caused an increase in fatty streak area at 26 weeks of age. In contrast to Moazed et al. [58] , we could not detect a significant difference in aortic lesions of mice infected at 10 or 12 weeks of age and killed at 20 weeks of age. We did not investigate earlier time points after acute infection.
These differences in results may be due to differences in strain, inoculum, or methodology. In both studies, the majority of mice 8 weeks after infection had C. pneumoniae detected by Figure 3 . Qualitative comparisons of mean aortic lesion areas between inoculated and control apolipoprotein E null mice. Mice were sham inoculated or inoculated with Chlamydia pneumoniae, were treated with placebo or with azithromycin, and were killed. This experiment was performed twice: set 1 (left), mice were inoculated at weeks 10 and 12, were treated at weeks 14 and 15, and were killed at week 20; set 2 (right), mice were inoculated at weeks 12 and 14, were treated at weeks 16 and 17, and were killed at week 26. Five sections of each proximal aorta were stained with oil red O (ORO) and hematoxylin; area of ORO staining was measured by computer analysis. Data are of 20 mice/group. In mice inoculated with C. mean ‫ע‬ SD pneumoniae at weeks 12 and 14, aortic lesions were larger at week 26 than those in sham-inoculated mice (* ). Treatment with azithro-P ! .01 mycin had no effect, compared with placebo.
PCR in the lung. In our study, we detected organism in aorta in a smaller percentage of mice (in only 1 of 10 mouse aortas at 26 weeks of age). Despite the fewer PCR-positive tissues, the antibody titer was higher and remained higher in this experiment, compared with the findings of Moazed et al. [58] .
One important finding of our study is that infected animals have an increase in lesion size, although the acute infection has resolved. This increase may be due to the initial active infection or may be due to a latent infection, which may be more a proatherogenic than an active infection. However, it is also possible that plaque formation is exacerbated not by active or latent infection but, rather, by a persistent immune response to an infection that has resolved.
Another important finding of our study is that azithromycin treatment has no effect on aortic lesion size after infection. The effect of antibiotic treatment on atherosclerosis has not been assessed previously in the mouse model. Data in the rabbit model show that much higher doses of azithromycin given 2 weeks after the initial inoculation also have no effect on lesion area; however, treatment 5 days after inoculation reduces atherosclerosis [18] . Treatment this early after infection may inhibit active infection completely, since the life cycle of C. pneumoniae is 72 h. One potential limitation of our study is that, although there is an effect of azithromycin, the effect was not detectable in a study of this size. Our data, together with those from the rabbit study, suggest that antibiotics administered long after infection may have no effect on atherogenesis. However, early treatment of the acute infection may reduce the proatherogenic effect of C. pneumoniae infection.
Azithromycin was chosen for this experiment because of its long half-life and its high tissue concentrations. Previous studies showed that a single 10-mg/kg dose is adequate to cure C. pneumoniae pneumonitis in the mouse [68] . Although cultures are negative after antibiotic treatment, C. pneumoniae DNA is readily detected by PCR, and pulmonary infection can be reactivated with steroid therapy [69] [70] [71] . The 24-mg/kg dose administered to mice in our study is comparable with the 21-mg/ kg dose (1.5 g/70 kg) given to adults for chlamydial respiratory infections.
Another finding of our study is that azithromycin treatment has no effect upon aortic lesion size in noninfected mice. Macrolide antibiotics have anti-inflammatory effects [72] . For example, macrolide antibiotics can inhibit superoxide production by activated neutrophils in vitro [67] . Macrolide antibiotics reduced levels of tumor necrosis factor-a, interleukin-1b, prostaglandin E2, and nitrite in several in vivo models of inflammation [65, 66] . Since atherosclerosis is an inflammatory disease, we hypothesized that azithromycin would decrease the size of aortic lesions in noninfected mice, compared with that of noninfected and nontreated mice. However, azithromycin had no effect on aortic lesion size in noninfected mice.
Our data suggest that an initial C. pneumoniae infection that subsequently resolves can have long-term effects on atherogenesis. Treatment of this infection after 4-5 weeks with antibiotics had no protective effect on the development of atherogenesis. These 2 observations taken together support the hypothesis that the initial injury of C. pneumoniae leads to an exacerbation of atherogenesis, perhaps by stimulating an immune response or by directly damaging the vessel wall and stimulating a repair response within the vessel wall. Another possibility is that persistent C. pneumoniae infection that is not eradicated by azithromycin contributes to atherogenesis by continually causing inflammation of the vessel wall.
Several large clinical trials are underway to examine the role of antibiotics in secondary prevention of heart disease by treating patients long after initial infection. The clinical implications of our data suggest that the treatment of C. pneumoniae several weeks after the acute infection might have no effect on the proatherogenic effect of infection in a primary prevention trial. However, our data did not determine whether antibiotics are beneficial in secondary prevention trials, in which plaque instability may be exacerbated by subsequent inflammation due to reinfection or reactivation of C. pneumoniae infection.
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